NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Aidoc, the leading provider of healthcare AI solutions, today announced it has increased its FDA clearances to 11 with the addition of CT-based AI solutions - aortic dissection (AD) and all vessel occlusions (VOs). These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.
With increased pressure on health systems due to the provider labor shortage, rising costs and COVID-19's ongoing impact, the need to provide more cost-effective quality care through earlier, faster treatment and more accurate interventions is imperative. Aidoc's clinical AI improves clinician efficiency, decreases the length of stay, and reduces turnaround time to mitigate average hospital costs, rising 15-25% since 20201.
These Aidoc solutions enable care teams across multiple service lines to not only identify patients in need of escalated care but further enhance cross-specialty provider workflows leading to decreased time to treatment and improved transfers, which may result in additional care-improving procedures.
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
"Effective healthcare and treatment of acute conditions, like stroke and aortic dissections, require rapid, coordinated care– minutes can matter," said Aidoc CEO Elad Walach. "Our continued momentum with FDA-cleared solutions are not only aiding radiologists to prioritize potential findings, but we are helping connect other care team members immediately to the data needed to drive next actions and an optimized care plan. This leads to improved patient outcomes, such as reduced length of stay, and eases the communication burden on the care team because the right people are notified and engaged together."
Aidoc Gains First-Time FDA-Clearance to Flag All Large and Medium Vessel Occlusions
While existing products in the market detect only middle cerebral artery (MCA) M1 or internal carotid artery (ICA) occlusions, the latest vessel occlusion (VO) solution makes Aidoc the first and only company to gain clearance for triage and notification of all intracranial large VOs (LVOs) and more distal medium VOs (MeVOs) in the MCA, ICA, anterior cerebral artery (ACA), posterior cerebral artery (PCA), vertebral artery (VA) and basilar artery (BA). Now stroke teams have an option for an AI-driven workflow within a mobile app that provides reliable notification and convenient access to critical patient information and imaging for all LVO and MeVO patients - conditions where every minute matters.
